Armata Pharmaceuticals, Inc. 8-K

What Happened
Armata Pharmaceuticals, Inc. (ARMP) announced on a Form 8-K (filed Jan 26, 2026) that it entered into amendments with Innoviva Strategic Opportunities LLC (a wholly owned subsidiary of principal shareholder Innoviva, Inc.) to extend the maturity dates of four existing credit agreements and to extend the expiration dates of four outstanding warrant certificates. The company also amended its Second Amended and Restated Voting Agreement with Innoviva to change the agreement’s expiration condition.

Key Details

• Four credit agreements (entered or amended in Jan 2023, July 2023, March 2024 and March 2025) were amended to extend the maturity date to June 1, 2027.
• Four warrant certificates were amended to extend expiration to January 26, 2031 for warrants covering: 1,807,396; 2,692,604; 1,867,912; and 4,285,935 shares (totaling 10,653,847 shares).
• The Voting Agreement amendment sets the expiration to the earlier of (i) January 26, 2031 or (ii) FDA approval of any Armata product candidate for marketing and commercial distribution.
• Amendments were executed with Innoviva Strategic Opportunities LLC (Innoviva Sub) and dated January 23, 2026.

Why It Matters
These amendments push near-term debt maturities out to mid-2027, which affects Armata’s short-term financing timeline and reduces the immediate risk of repayment or refinancing pressure. Extending warrant expirations delays potential dilution from those warrants until 2031, which investors should consider when assessing future share count and dilution risk. The voting agreement extension preserves Innoviva’s governance arrangements with Armata until 2031 or until an FDA approval event occurs, which may influence corporate voting outcomes and strategic decision-making while the agreement remains in effect.